Entry

D11530                      Drug

Name

Sutimlimab (USAN/INN);
Sutimlimab (genetical recombination) (JAN);
Sutimlimab-jome;
Enjaymo (TN)

Product

ENJAYMO (Bioverativ U.S. LLC.)

Formula

C6436H9912N1700O2016S46

Exact mass

144743.2507

Mol weight

144832.7369

Sequence

(Heavy chain)
EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQA PGKGLEWVAT ISSGGSHTYY
LDSVKGRFTI SRDNSKNTLY LQMNSLRAED TALYYCARLF TGYAMDYWGQ GTLVTVSSAS
TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFEGGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV
FSCSVMHEAL HNHYTQKSLS LSLGK
(Light chain)
QIVLTQSPAT LSLSPGERAT MSCTASSSVS SSYLHWYQQK PGKAPKLWIY STSNLASGVP
SRFSGSGSGT DYTLTISSLQ PEDFATYYCH QYYRLPPITF GQGTKLEIKR TVAAPSVFIF
PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST
LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC
(Disulfide bridge: H22-H96, H132-L216, H145-H201, H224-H'224, H227-H'227, H259-H319, H365-H423, H'22-H'96, H'132-L'216, H'145-H'201, H'259-H'319, H'365-H'423, L23-L89, L136-L196, L'23-L'89, L'136-L'196)

Type

Peptide

Remark

Therapeutic category:

6399

ATC code:

L04AA55

Product:

D11530<JP/US>

Efficacy

Anti-anemic, Anti-complement C1s antibody

Disease

Cold agglutinin disease [DS:H01585]

Comment

Monoclonal antibody

Target

C1S [HSA:716] [KO:K01331]

Pathway

hsa04610

Complement and coagulation cascades

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA55 Sutimlimab
      D11530  Sutimlimab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11530  Sutimlimab (USAN/INN); Sutimlimab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
  Hydrolases (EC3)
   Serine peptidases
    C1S
     D11530  Sutimlimab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11530
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D11530
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11530

Other DBs

CAS:	2049079-64-1

PubChem:

384585506